The case for & against
Bull & Bear analysis
Merck & Company, Inc. (NYSE: MRK) is a leading global biopharmaceutical company that focuses on developing innovative therapies across several therapeutic areas, including oncology, infectious diseases, cardiometabolic conditions, and animal health. Merck is strategically positioned within the healthcare sector, utilizing a robust pipeline for sustainable growth as it navigates competitive pressures and regulatory challenges. With products such as Keytruda, the company is well-known for its contributions to cancer treatment, while also actively pursuing advancements in vaccines and animal health solutions.
Bull says
- ↑2026 revenue guided to $65.8–67B (1–3% growth)
- ↑Keytruda sales rose 8% YoY to $8B; oncology demand strong
- ↑~$3B share repurchase plan plus 0.74% dividend yield
- ↑Pipeline targets $70B commercial opportunity by mid-2030s
- ↑High earnings and dividend yields; strong leverage, low volatility
- ↑Animal health sales +6%; livestock segment +8% growth
Bear says
- ↓Keytruda patent expires 2028, risking ~50% of revenues
- ↓Generic competition could cut sales by ~$2.5B
- ↓Gardasil sales declined 22% due to weak demand in China/Japan
- ↓Over 20 new launches remain unproven; adoption uncertain
- ↓OpEx rising to $35.9–36.9B may pressure margins
- ↓Weak growth and revisions metrics; institutional interest declining
Investment themes with MRK
Companies paying above-average dividends
Companies with strong fundamentals and stability
Drug development driving global healthcare solutions
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- we delivered growth in the quarter driven by continued strength in oncology and animal health, as well as increasing contributions from our many compelling product launches.
- total company revenues were $16.3 billion, an increase of 5%.
- increased 8% to $8 billion, with global growth driven by continued strong demand from metastatic indications and robust uptake in earlier stage cancers.
Bear points
- Gardasil sales were $1.1 billion, a decrease of 22%, driven by lower demand in China and Japan, consistent with our expectations.
- Sales of Otover, a novel maintenance treatment for adults with COPD, were $131 million. As expected, sales were adversely impacted by the CMS reimbursement change as well as Medicare deductible resets.
- As announced last week with our partner, ASI, the combination regimens from the LightSpark 012 study did not meet the dual primary endpoints of progression-free survival and overall survival for the first-line treatment of patients with RCC compared to Keytruda plus Lemvima.